SOURCE: Biophan Technologies

May 05, 2006 07:00 ET

Biophan Chosen as Latest EQUITIES Special Situation!

LOS ANGELES, CA -- (MARKET WIRE) -- May 5, 2006 -- Biophan Technologies, Inc. (OTC BB: BIPH); (FWB: BTN), Henrietta, NY-based pioneer of next-generation medical technology, was the May BUY recommendation of EQUITIES Special Situations, edited by legendary financial journalist Bob Flaherty. Equities Special Situations aims for a 50% to 100% gain in Biophan's stock price within two years. Equities recommended OTC BB: BIPH at $1.53.

EQUITIES Special Situations Beats the Wilshire Index four years in a row!

With one of the best and most consistent performances among top stock advisory newsletters for 2002, 2003, 2004 and 2005, according to The Hulbert Financial Digest, EQUITIES has beaten the Wilshire 5000 index four straight years, gaining 14.78% versus 6.2% for the Index in 2005! Naturally, past performance is no guarantee of future success.

Why Biophan?

Biophan's progress in pioneering and patenting devices to make MRI safer is impressive. Currently, pacemakers, defibrillators, and other implanted devices are dangerous when imaged under MRI (Magnetic Resonance Imaging). In fact, getting MRI with an implant can kill you. So can skipping MRI. But fear not, Biophan has found a cure for this dilemma by pioneering advanced medical technologies that are MRI safe -- solving problems that prevent over 34 million people from getting MRIs when needed.

Biophan allows the following devices to be MRI safe and compatible for the first time: Stents, Vena Cava Filters, Pacemakers, other Pacing Devices, Guidewires, Catheters, Motors for Implantable Drug Pumps and Devices and Left Ventricular Assist Devices (LVADs).

About Biophan -- A Unique Company

Biophan has no direct competition and is the only company that develops biomedical devices that are safe and image compatible with magnetic resonance imaging (MRI). Naturally, the giants are working on this problem too.

Other Technologies / Applications

Biophan is helping to commercialize the MYO-VAD™, a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat.

Strong IP Position

Biophan currently has 212 patents, pending and issued, on technology covering a wide range of medical applications.

Strategic Partnerships

May 2, 2006 -- Biophan announced that it has entered into a research partnership with the US Food and Drug Administration (FDA) to help improve patient safety in Magnetic Resonance Imaging (MRI) environments. In addition, the company secured a partnership with Boston Scientific Medical in August 2005. Also, Biophan has secured a joint development agreement with NASA Ames Research Center to develop innovative power sources for implantable devices that derive energy from body heat.

Experienced Management

Biophan's experienced management team has a history of creating successful start-ups. Also, prominent scientists such as Herbert Hauptman, winner of the 1985 Nobel Prize in Chemistry, comprise the company's first-rate scientific advisory board.

To get the in-depth report on why EQUITIES believes that Biophan is a BUY, go to and view the full report for the first time online while it's still hot! We usually post our award-winning Special Situations three to four weeks after it goes to our subscribers. But not this time! This time we're letting you view it for free right away! Don't miss out, click the link!

To subscribe to EQUITIES Special Situations:

Disclaimer: Some statements may contain so-called "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made herein. These forward-looking statements are not historical facts, but reflect current expectations, estimates and projections. No assurance is given that these estimates, expectations or projections will be achieved. Many factors could cause actual results to differ. Investors should consult with their investment advisor, attorneys and other professionals concerning any stock transaction. Equities Magazine has relied upon information supplied by its customers, which it believes to be reliable; however, such reliability cannot be guaranteed. Equities Magazine makes no representations as to the accuracy, timeliness or completeness of the information contained in any such advertisement and disclaims any and all liability relating thereto. Equities Magazine is not responsible for any claims made by the companies advertised herein. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Equities Magazine urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Equities Magazine does not offer such advice or analysis, and Equities Magazine further urges you to consult your own independent tax, business, financial and investment advisors. Equities Magazine has been paid $12,000 by Biophan to attend two past EQUITIES conferences.

Contact Information

  • EQUTIES Magazine Contact Info
    EQUITIES Global Communications, LLC
    Jonathan Bernard
    Director of Communications
    Email Contact

    Biophan Contact Info
    Biophan Technologies, Inc.
    Carolyn Hotchkiss
    Press Interviews:
    Jennifer Gould